Eckert & Ziegler to Supply Canadian Alpha-9 Theranostics with Lutetium-177 for Clinical Trials

in

BOSTON, Mass. and VANCOUVER, British Columbia, March 23, 2022 – Eckert & Ziegler (ISIN DE0005659700, TecDAX) has executed with the Canadian biotech company Alpha-9 Theranostics Inc. (Alpha-9) a clinical supply agreement for Eckert & Ziegler’s medical radioisotope Lutetium-177 (non-carrier-added 177Lu). The isotope will be used for the clinical development of Alpha-9´s investigational drugs.

Eckert & Ziegler has developed a unique, stable and reliable method to produce a highly pure form of n.c.a. Lu-177 which will be used by Alpha-9 for the clinical trials of its therapeutic candidates for solid and hematologic malignancies.

Lutetium-177 is a beta emitting radioisotope that can be linked to a variety of tumor specific drugs which then incorporates the radiating element of the radioisotope into the tumor cells.

“The supply contract with Canada-based Alpha-9 further underlines our outstanding expertise in supplying isotopes to the pharmaceutical industry. With production sites in Europe, Asia, and North America, we are excellently positioned to meet the growing demand for relevant isotopes and the associated development and production services,” explained Dr. Harald Hasselmann, Executive Director and responsible for the Medical segment of Eckert & Ziegler. “Our recently concluded joint venture with Atom Mines LLC provides us with excellent access to the scarce and indispensable precursor ytterbium-176, enabling us to supply lutetium-177 n.c.a. in highest purity and reliably to pharmaceutical customers worldwide.”

Alpha-9 is committed to developing its portfolio and exploring potential therapies to help patients. Alpha-9 is looking forward to its partnership with Eckert Ziegler and the potential that this partnership creates to advance radioligand therapy.

Targeted radionuclide therapy with Lutetium-177, currently under late-stage clinical development for several types of cancer, may provide a valuable alternative treatment option in the field of precision oncology.

About Eckert & Ziegler.

Eckert & Ziegler Strahlen- und Medizintechnik AG with more than 900 employees is one of the world’s largest providers of isotope-related components for nuclear medicine and radiation therapy. The company offers services for radiopharmaceuticals at its worldwide locations, from early development to commercialization. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse. Contributing to saving lives.

About Alpha-9 Theranostics

Alpha-9 Theranostics is a clinical stage, radiopharmaceutical company developing imaging and therapeutic molecules for solid and hematologic malignancies. Using proprietary technology and the Company’s expertise, these differentiated molecules have the potential to meaningfully extend patients’ lives with favorable safety profiles.

Alpha-9 Theranostics Announces $11 Million Series A Financing to Advance Portfolio of Radiotherapeutics and Diagnostics

in

VANCOUVER, British Columbia, April 28, 2021 — Alpha-9 Theranostics Inc. announced today an $11 million Series A financing to advance a portfolio of novel radiotherapeutics and diagnostics. Longitude Capital led the financing with participation from BVF Partners L.P. and insiders. “We are delighted that Longitude and BVF are investing in Alpha-9,” said Simon Pimstone, MD, PhD, Chairman of the Board of Directors. “These high-quality investors share our conviction in the promise of radiotherapeutics and diagnostics.” David Hirsch, MD, PhD of Longitude Capital remarked, “Alpha9 is an exciting company, founded by leaders in the field, with a growing portfolio of novel assets. We believe that radiotherapeutics have the potential to deliver on the promise of precision oncology and we look forward to working with the Alpha-9 team to advance multiple programs into clinical trials.”

About Alpha-9

Alpha-9 Theranostics is a clinical stage, radiopharmaceutical company developing imaging and therapeutic molecules for solid and hematologic malignancies. Using proprietary technology and the Company’s expertise, these differentiated molecules have the potential to meaningfully extend patients’ lives with favorable safety profiles. Alpha-9 was founded by researchers from the University of British Columbia and BC Cancer, with the goal of improving the lives of patients affected by metastatic cancers. For more information, please visit www.alpha9tx.com.

About Longitude Capital

Longitude Capital is a leading healthcare venture capital firm that invests in transformative biotechnology, medical technology and health solutions companies seeking to improve clinical outcomes, enhance quality of life, and drive efficiency of healthcare delivery. Founded in 2006, Longitude Capital invests in both privately held and publicly traded companies through a variety of investment approaches. Longitude Capital has offices in Menlo Park, CA, Greenwich, CT, and Boston, MA. For more information, please visit www.longitudecapital.com or LinkedIn.